Recombinant monoclonal antibody to IGF1 Receptor. Figitumumab (previously CP-751871) is a monoclonal antibody targeting the insulin-like growth factor-1 receptor being investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small

Recombinant monoclonal antibody to IGF1 Receptor. Robatumumab (proposed INN) is a monoclonal antibody and an antineoplastic by Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor.Suitable for use in FuncS, IF, Neut, ELISA,

Recombinant monoclonal antibody to IGF1 Receptor. Cixutumumab is a monoclonal antibody for the treatment of solid tumors. It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with